Tag Archives: NASDAQ:ATRC

Needham Believes Atricure (NASDAQ: ATRC) Still Has Room to Grow

In a report released today, Michael Matson from Needham assigned a Buy rating to Atricure (ATRC – Research Report), with a price target of $49.00. The company’s shares closed last Friday at $41.09, close to its 52-week high of $44.51.

BTIG Believes Atricure (NASDAQ: ATRC) Still Has Room to Grow

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Atricure (ATRC – Research Report), with a price target of $45.00. The company’s shares closed last Wednesday at $41.39, close to its 52-week high of $44.51.

Atricure (ATRC) Received its Third Buy in a Row

After Needham and Piper Sandler gave Atricure (NASDAQ: ATRC) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Suraj Kalia maintained a Buy rating on Atricure today and set a price target of $45.00.

Atricure (ATRC) Receives a Rating Update from a Top Analyst

In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC – Research Report), with a price target of $51.00. The company’s shares closed last Monday at $43.16, close to its 52-week high of

Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Medtronic (MDT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), Medtronic (MDT – Research Report) and Acasti Pharma (ACST – Research Report) with bullish sentiments. Atricure (ATRC)

BTIG Initiates a Buy Rating on Atricure (ATRC)

In a report released yesterday, Marie Thibault from BTIG initiated coverage with a Buy rating on Atricure (ATRC – Research Report) and a price target of $42.00. The company’s shares closed last Monday at $38.63, close to its 52-week high